Maryland has increased power over drug prices

INICIO/Políticas y legislación | Posted 21/04/2017 post-comment0 Post your comment

The US Food and Drug Administration (FDA) announced on 2 March 2017 that the state of Maryland General Assembly was considering two bills that would require pharmaceutical companies to notify the state ahead of drug price increases. On 20 March 2017, one of these bills that sets out to ban excessive price increases for generics and off-patent drugs, was passed. In the US, legislation related to pharmaceuticals can vary across states [1].

88 MD002468

FDA reported that the bill that will ban ‘price gouging’ was approved by the Maryland House of Delegates in a 137−4 vote. Thus, the legislation has now been advanced to the senate. This bill applies to essential generic medicines on the World Health Organization list. It also includes consideration of off-patient treatments that are not subject to significant market competition and would prohibit increases in prices of these products that are described as ‘excessive and not justified by the cost of producing the drug’. Should the price of a drug need to be increased, the Maryland Medical Assistance Program would be required to notify the Attorney General. The manufacturer of the specified drug would need to submit an accompanying statement within 20 days of the request being made.

It is reported that the bill will also allow the state’s attorney general to sue drug manufacturers if they are found to be price gouging. Court proceedings would determine if the increased price is ‘unconscionable’, and if it has any effects on the access to a critical therapy. Potential penalties for non-compliance are reported to be in the region of US$10,000 per day of non-compliance. 

The second bill that the assembly is considering would require drug manufacturers with a wholesale acquisition cost of over US$2,500 per year or course of treatment, to submit an annual report for all products. It is reported that these reports would include: research and development costs; manufacturing, advertising and regulatory costs; amounts spent on patient assistance programmes; and the company’s tax rates and received credits, in addition to the profits made. Again, failure to comply would carry penalties of US$10,000 per day for non-compliance.

Related articles
FDA amends citizen petition rules to reduce delays to generics and biosimilars

New bill would stop brand-name pharma restricting drug samples

1. GaBI Online - Generics and Biosimilars Initiative. More US state legislation on biosimilars substitution []. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Apr 21]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Generic ‘skinny’ labelling under threat in the US
Label prescription drugs
INICIO/Políticas y legislación Posted 05/11/2021
Lawsuits and US$450 million payout for price fixing and delayed generics entry
34 AA010660
INICIO/Políticas y legislación Posted 29/10/2021
FDA publishes final Q&A on biosimilar development and the BPCI Act
INICIO/Políticas y legislación Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
INICIO/Políticas y legislación Posted 08/10/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010